Buys | $350,430 | 1 | 6 |
Sells | $5,685,357 | 16 | 94 |
Henderson Jeffrey William | director | 1 | $350,430 | 0 | $0 | $350,430 |
Spoerel Thomas J | SVP,Controller&Chief Acct Off | 0 | $0 | 1 | $71,793 | $-71,793 |
SCOTT BERTRAM L | director | 0 | $0 | 1 | $159,593 | $-159,593 |
Shan David | EVP and Chief ISC Officer | 0 | $0 | 2 | $450,375 | $-450,375 |
Byrd Richard | EVP & President Interventional | 0 | $0 | 2 | $541,895 | $-541,895 |
Neal Shana Carol | EVP and Chief People Officer | 0 | $0 | 3 | $594,550 | $-594,550 |
Garrison Michael David | EVP & President Medical | 0 | $0 | 3 | $1.17M | $-1.17M |
Goette Roland | EVP and President EMEA | 0 | $0 | 4 | $2.69M | $-2.69M |
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Over the last 12 months, insiders at Becton, Dickinson and Company have bought $350,430 and sold $5.69M worth of Becton, Dickinson and Company stock.
On average, over the past 5 years, insiders at Becton, Dickinson and Company have bought $350,430 and sold $4.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Henderson Jeffrey William (director) — $350,430.
The last purchase of 1,500 shares for transaction amount of $350,430 was made by Henderson Jeffrey William (director) on 2025‑02‑10.
2025-03-18 | Sale | Byrd Richard | EVP & President Interventional | 459 0.0002% | $230.00 | $105,570 | -0.14% | |
2025-03-12 | Sale | Byrd Richard | EVP & President Interventional | 1,940 0.0007% | $224.91 | $436,325 | +2.86% | |
2025-02-12 | Sale | SCOTT BERTRAM L | director | 700 0.0002% | $227.99 | $159,593 | -0.53% | |
2025-02-10 | Henderson Jeffrey William | director | 1,500 0.0005% | $233.62 | $350,430 | -1.59% | ||
2025-01-21 | Sale | Neal Shana Carol | EVP and Chief People Officer | 787 0.0003% | $240.00 | $188,880 | -4.87% | |
2025-01-21 | Sale | Shan David | EVP and Chief ISC Officer | 500 0.0002% | $240.00 | $120,000 | -4.87% | |
2025-01-17 | Sale | Garrison Michael David | EVP & President, Medical | 597 0.0002% | $236.51 | $141,196 | -3.61% | |
2025-01-07 | Sale | Neal Shana Carol | EVP and Chief People Officer | 788 0.0003% | $235.00 | $185,180 | -0.87% | |
2024-12-19 | Sale | Garrison Michael David | EVP & President, Medical | 2,838 0.001% | $223.33 | $633,811 | +2.22% | |
2024-12-09 | Sale | Goette Roland | EVP and President, EMEA | 638 0.0002% | $219.03 | $139,741 | +2.41% | |
2024-12-06 | Sale | Goette Roland | EVP and President, EMEA | 4,483 0.0016% | $221.01 | $990,788 | +4.24% | |
2024-12-06 | Sale | Neal Shana Carol | EVP and Chief People Officer | 1,000 0.0003% | $220.49 | $220,490 | +4.24% | |
2024-12-05 | Sale | Shan David | EVP and Chief ISC Officer | 1,500 0.0005% | $220.25 | $330,375 | +3.13% | |
2024-06-10 | Sale | Spoerel Thomas J | SVP,Controller&Chief Acct Off | 300 0.0001% | $239.31 | $71,793 | -2.30% | |
2024-05-15 | Sale | Goette Roland | EVP and President EMEA | 3,300 0.0011% | $236.73 | $781,224 | -1.00% | |
2024-05-13 | Sale | Goette Roland | EVP and President EMEA | 3,300 0.0011% | $236.70 | $781,121 | -0.84% | |
2024-04-30 | Sale | Garrison Michael David | EVP & President Medical | 1,715 0.0006% | $232.81 | $399,269 | +0.17% | |
2024-03-14 | Sale | Spoerel Thomas J | SVP,Controller&Chief Acct Off | 282 <0.0001% | $238.29 | $67,198 | -0.83% | |
2023-12-11 | Sale | Garrison Michael David | EVP & President Medical | 1,239 0.0004% | $232.46 | $288,018 | +1.87% | |
2023-11-28 | Sale | Byrd Richard | EVP & President Interventional | 2,156 0.0007% | $238.47 | $514,141 | +0.61% |
SCOTT BERTRAM L | director | 36033 0.0125% | $8.3M | 0 | 3 | |
Neal Shana Carol | EVP and Chief People Officer | 15414 0.0054% | $3.55M | 0 | 3 | |
Goette Roland | EVP and President, EMEA | 14217 0.005% | $3.27M | 0 | 6 | |
Henderson Jeffrey William | director | 8015 0.0028% | $1.85M | 1 | 0 | |
Byrd Richard | EVP & President Interventional | 6952 0.0024% | $1.6M | 0 | 5 | |
Shan David | EVP and Chief ISC Officer | 5741 0.002% | $1.32M | 0 | 2 | |
Garrison Michael David | EVP & President, Medical | 5544 0.0019% | $1.28M | 0 | 5 | |
Spoerel Thomas J | SVP,Controller&Chief Acct Off | 1976 0.0007% | $454,934.48 | 0 | 7 | |
FORLENZA VINCENT A | Chairman of the Board | 208864 0.0727% | $48.09M | 0 | 26 | |
LUDWIG EDWARD J | Chairman | 97188 0.0338% | $22.38M | 0 | 39 | |
RING TIMOTHY M | director | 93688 0.0326% | $21.57M | 0 | 3 | |
CONSIDINE JOHN R | Vice Chairman | 89650 0.0312% | $20.64M | 0 | 7 | |
COHEN GARY M | Executive Vice President | 71770 0.025% | $16.52M | 0 | 21 | |
KOZY WILLIAM A | Executive Vice President | 68823 0.024% | $15.85M | 0 | 23 | |
HANSON ALFRED JOHN | Executive Vice President | 40273 0.014% | $9.27M | 0 | 5 | |
Polen Thomas E Jr | Chairman, CEO and President | 28878 0.0101% | $6.65M | 0 | 10 | |
BECTON HENRY P JR | director | 23820 0.0083% | $5.48M | 0 | 56 | |
ORR JAMES F | director | 23045 0.008% | $5.31M | 0 | 3 | |
SHERMAN JEFFREY S | Sr. VP and General Counsel | 22094 0.0077% | $5.09M | 0 | 17 | |
Fraser Claire | director | 21608 0.0075% | $4.97M | 0 | 7 | |
Conroy Alexandre | EVP of Integrated Supply Chain | 21260 0.0074% | $4.89M | 0 | 8 | |
OVERLOCK WILARD J JR | director | 21091 0.0073% | $4.86M | 2 | 2 | +1.24% |
Mecklenburg Gary A | director | 20965 0.0073% | $4.83M | 0 | 1 | |
Lim James C | Executive Vice President | 19768 0.0069% | $4.55M | 0 | 10 | |
DEGRAAN EDWARD | director | 18608 0.0065% | $4.28M | 0 | 1 | |
ANDERSON BASIL | director | 17221 0.006% | $3.96M | 0 | 1 | |
SOMMER ALFRED | director | 16228 0.0057% | $3.74M | 0 | 5 | |
Boles Donna M | Senior VP - Human Resources | 14607 0.0051% | $3.36M | 0 | 8 | |
TOZZI WILLIAM A | EVP Pres Interventional | 13208 0.0046% | $3.04M | 0 | 13 | |
Tharby Linda M | Executive Vice President | 11337 0.0039% | $2.61M | 0 | 4 | |
Campion Simon D | EVP and Segment President | 10773 0.0038% | $2.48M | 0 | 2 | |
RIMEL REBECCA W | director | 10618 0.0037% | $2.44M | 0 | 6 | |
Kaltenbach Patrick | EVP & Pres Life Sciences | 10340 0.0036% | $2.38M | 0 | 9 | |
UGGLAS MARGERETHA AF | director | 10000 0.0035% | $2.3M | 1 | 0 | +22.53% |
BURZIK CATHERINE M | director | 10007 0.0035% | $2.3M | 3 | 1 | +5.53% |
BEATY HARRY N | director | 9204 0.0032% | $2.12M | 0 | 1 | |
DURACK DAVID T | Senior Vice President | 8382 0.0029% | $1.93M | 0 | 22 | |
Mas Ribo Alberto | EVP and Pres, Life Sciences | 8381 0.0029% | $1.93M | 0 | 6 | |
SHRADER PATRICIA B | Senior Vice President | 7915 0.0028% | $1.82M | 0 | 4 | |
Sichak Stephen | Executive Vice President | 7953 0.0028% | $1.83M | 0 | 11 | |
Bruder Scott P | SrVP; Chief Technology Officer | 7626 0.0027% | $1.76M | 0 | 1 | |
Shabshab Nabil | Executive Vice President | 7811 0.0027% | $1.8M | 0 | 5 | |
Strahlman Ellen R | Senior Vice President | 6037 0.0021% | $1.39M | 0 | 2 | |
Khichi Samrat S. | EVP and General Counsel | 5928 0.0021% | $1.36M | 0 | 3 | |
Larson Betty D | EVP HR & CHRO | 5872 0.002% | $1.35M | 0 | 3 | |
Elkins David V | Executive VP and CFO | 5513 0.0019% | $1.27M | 0 | 1 | |
DAGEVILLE JEAN MARC | VP - Human Resources | 4658 0.0016% | $1.07M | 0 | 1 | |
Hickey David | EVP & President, Life Sciences | 4199 0.0015% | $966,735.77 | 0 | 4 | |
Hurwitz Jerome V | Executive Vice President | 3027 0.0011% | $696,906.21 | 0 | 4 | |
Minehan Cathy E. | director | 3000 0.001% | $690,690.00 | 2 | 0 | +2.05% |
Melcher David F | director | 2728 0.001% | $628,067.44 | 1 | 0 | +8.76% |
Borzi James W | EVP & Chief Supply Chain Offcr | 2775 0.001% | $638,888.25 | 0 | 2 | |
Gallagher John E | VP, Corp Finance and Treasurer | 2099 0.0007% | $483,252.77 | 0 | 5 | |
Bodner Charles R | SVP Corp Fin Chief Acct Office | 2037 0.0007% | $468,978.51 | 0 | 2 |
Increased Positions | 744 | +40.74% | 26M | +9.99% |
Decreased Positions | 795 | -43.54% | 19M | -7.53% |
New Positions | 196 | New | 5M | New |
Sold Out Positions | 139 | Sold Out | 3M | Sold Out |
Total Postitions | 1,775 | -2.79% | 264M | +2.47% |
Vanguard Group Inc | $6.04M | 9.32% | 26.74M | +184,288 | +0.69% | 2024-12-31 |
Blackrock, Inc. | $5.42M | 8.36% | 23.98M | +2M | +7.68% | 2024-12-31 |
State Street Corp | $3.18M | 4.91% | 14.09M | +134,357 | +0.96% | 2024-12-31 |
Price T Rowe Associates Inc /Md/ | $2.79M | 4.3% | 12.35M | -1M | -9.21% | 2024-12-31 |
T. Rowe Price Investment Management, Inc. | $2.74M | 4.22% | 12.13M | +3M | +36.14% | 2024-12-31 |
Morgan Stanley | $2.31M | 3.57% | 10.24M | -742,840 | -6.76% | 2024-12-31 |
Geode Capital Management, Llc | $1.44M | 2.21% | 6.35M | +66,024 | +1.05% | 2024-12-31 |
Massachusetts Financial Services Co /Ma/ | $1.4M | 2.15% | 6.18M | +810,345 | +15.1% | 2024-12-31 |
Generation Investment Management Llp | $1.31M | 2.03% | 5.82M | -139,252 | -2.34% | 2024-12-31 |
First Eagle Investment Management, Llc | $1M | 1.54% | 4.43M | +1M | +31.41% | 2024-12-31 |